Article

Intermittent hormonal therapy shows similar outcome than SOC in ER+ breast cancer preclinical model

2019-01-02

Abstract excerpt

Clinical breast cancers in which at least 10% of cells express the estrogen receptor are labeled as “ER positive.” First line therapy for these patients is typically continuous administration of anti-estrogen drugs at maximum tolerated dose (MTD) until progression. In the vast majority of patients, resistance to hormone therapy evolves in the breast cancer cells within 2 years leading to treatment failure and tumo...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 65bf7f6c-e11f-5578-a17b-e805f7fbccf8
DOI: 10.1101/509158

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Intermittent hormonal therapy shows similar outcome than SOC in ER+ breast cancer preclinical modelDOI 10.1101/509158Read

Mechanisms of aromatase inhibitor resistance.Semantic proximity Read

Molecular Mechanisms and Therapeutic Strategies to Overcome Resistance to Endocrine Therapy and CDK4/6 Inhibitors in Advanced ER+/HER2- Breast CancerSemantic proximity Read

A mechanistic model captures the emergence and implications of non-genetic heterogeneity and reversible drug resistance in ER+ breast cancer cellsSemantic proximity Read

Endocrine resistance in hormone-responsive breast cancer: mechanisms and therapeutic strategies.Semantic proximity Read

Convergent evolution of resistance pathways during early stage breast cancer treatment with combination cell cycle (CDK) and endocrine inhibitorsSemantic proximity Read

Endocrine therapy resistance: new insights.Semantic proximity Read

Ontogeny and Vulnerabilities of Drug-Tolerant Persisters in HER2+ Breast CancerSemantic proximity Read

Evolution of Resistance to Targeted Anti-Cancer Therapies during Continuous and Pulsed Administration StrategiesSemantic proximity Read

Estrogen Receptor Alpha Dynamics and Plasticity During Endocrine ResistanceSemantic proximity Read

Regulatory network and spatial modeling reveal cooperative mechanisms of resistance and immune escape in ER <sub>+</sub> breast cancerSemantic proximity Read

Drug resistance to targeted therapies: Déjà vu all over againSemantic proximity Read

On minimising tumoural growth under treatment resistanceSemantic proximity Read